Oppenheimer analyst Andreas Argyrides lowered the firm’s price target on InflaRx (IFRX) to $3 from $6 and keeps an Outperform rating on the shares. The firm notes InflaRx has announced that the IDMC recommended stopping the Phase 3 trial for vilobelimab, anti-C5a mAb, in PG due to futility following an unblinded interim analysis in 30 patients. With the discontinuation of vilo/PG, Oppenheimer removes it from its valuation as InflaRx shifts focus and resources to oral potent C5aR inhibitor, INF904 in HS and CSU.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IFRX:
- InflaRx downgraded to Outperform from Strong Buy at Raymond James
- InflaRx Stock (IFRX) Plummets 55% on Clinical Failure
- Morning News Wrap-Up: Wednesday’s Biggest Stock Market Stories
- InflaRx Halts Vilobelimab Phase 3 Trial for Pyoderma Gangrenosum
- InflaRx to discontinue vilobelimab indication following IDMC recommendation